Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).
Sukhmani K. Padda(Stanford University), Heather A. Wakelee(Palo Alto Institute), Joel W. Neal(Stanford Medicine), Robert B. West(Stanford University), Jonathan W. Riess(University of California Davis Medical Center), Holbrook Edwin Kohrt(Stanford University), Yasodha Natkunam(Palo Alto University), Erich Schwartz(Stanford Medicine), Lü Tian(Shandong University)
Cited by 2
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
|Cell|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k